Sumitomo Mitsui Trust Group Inc. Trims Stock Position in Gilead Sciences, Inc. $GILD

Sumitomo Mitsui Trust Group Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.3% during the 1st quarter, Holdings Channel reports. The firm owned 2,931,232 shares of the biopharmaceutical company’s stock after selling 337,885 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Gilead Sciences were worth $408,526,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC raised its holdings in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares during the last quarter. Quattro Advisors LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at $26,000. Wealth Preservation Advisors LLC lifted its position in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at $28,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the transaction, the insider directly owned 124,234 shares in the company, valued at $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,000 shares of company stock worth $10,824,500 over the last three months. 0.30% of the stock is owned by insiders.

Gilead Sciences Stock Down 0.4%

Shares of GILD opened at $135.82 on Thursday. Gilead Sciences, Inc. has a fifty-two week low of $107.75 and a fifty-two week high of $157.29. The company’s fifty day moving average is $129.64 and its two-hundred day moving average is $134.92. The firm has a market cap of $168.63 billion, a PE ratio of 18.50 and a beta of 0.32. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts forecast that Gilead Sciences, Inc. will post -0.81 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s payout ratio is 44.69%.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of recent research reports. Morgan Stanley dropped their price objective on Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday. The Goldman Sachs Group upped their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $133.00 to $155.00 in a research note on Monday. Truist Financial cut their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Rothschild & Co Redburn reduced their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Twenty-six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $159.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.